Kenya wins accolades for effective HIV fight
Kenya is the first country on the continent to put its prevention road map together.
It is also the second African country, after South Africa, to have pre-exposure prophylaxis guidelines.
More by this Author
Kenya's HIV prevention strategies are among the best and most workable in Africa, a global forum says.
Speaking yesterday at the third International HIV Research for Prevention Conference in Madrid, Spain, various experts gave presentations on the performance of selected countries.
Dr Linda Gail Bekker of the Desmond Tutu HIV Foundation in Cape Town, and immediate president of the International Aids Society, said Kenya' s response to HIV prevention should be supported.
"Kenya's response and approach to HIV prevention is the best in Africa. It is the first on the continent to put its prevention road map together, which is something we can't fail to mention," Dr Bekker said.
- 'Dangerous complacency' feared as AIDS conference opens
- Neutrophils could play role in HIV cure
She said that despite resource constraints, Kenya had ensured that pre-exposure prophylaxis drugs were available.
"There is a lot we can learn from Kenya. It has taken the hotspot mapping approach to ensure that those who need the drugs are not left out," she said.
Kenya is the second African country, after South Africa, to have pre-exposure prophylaxis guidelines.
Pre-exposure prophylaxis (PrEP) drugs join other prevention and treatment methods already in use. Other stra tegies include giving anti-retroviral (ARV) drugs to people who are not infected with HIV, but are at high risk of infection. These drugs reduce the chances of HIV infection.
In 2014, the World Health Organisation recommended offering PrEP to men who have sex with men, and in September broadened its recommendation to include all people at substantial risk of HIV infection as an additional prevention choice.
PrEP was first approved by the USA Food and Drug Administration (FDA) in 2012 before other countries followed suit.
The Kenya Pharmacy and Poisons Board approved use of oral PreP in December 2015.
In April last year, oral PrEP, the anti-retroviral drug Truvada, which is a combination of tenofovir and emtricitabine, was approved by the drug regulatory authority for use in the country.
When taken daily and consistently, the drug reduces new infections by 95 per cent.
According to d ata from PrEP Watch, the number of PrEP users in Kenya stands at 26,000 against 37,000, which is the overall target from all projects (planned and ongoing) being carried out in the country.
Mon Jul 23 15:30:00 EAT 2018
'Dangerous complacency' feared as AIDS conference opens
New HIV infections, while down overall, have surged in some parts of the world.
Schoolgirls yet to testify in âpredatorâ priest probe
The priest was suspended pending investigations by a tribunal.
Some varsity courses hyped: Ruto
DP advocates courses offered by technical and vocational education training colleges.